Ocular Therapeutix: chief development officer Peter Kaiser sold 9,990 shares

What happened Peter Kaiser, chief development officer, sold 9,990 shares of Ocular Therapeutix common stock on Oct 2, 2026. The filing reports a weighted-average price of $7.05 per share and total proceeds of $70,430.

Key details

• Transaction date: Oct 2, 2026.
• Transaction type: open market or private sale (code S).
• Price: weighted-average $7.05 per share; reported sales executed at prices ranging from $6.9900 to $7.1954.
• Shares sold: 9,990. Proceeds: $70,430.
• Shares owned after the transaction: not provided in the information given.
• Footnote F1: sales were made pursuant to a durable automatic sale instruction adopted Apr 9, 2024, as a sell-to-cover to satisfy tax withholding arising from restricted stock units that vested on Oct 1, 2026; the sales were not a discretionary trade by the reporting person.
• Footnote F2: price in Column 4 is a weighted average; the reporting person will provide details of the number of shares sold at each separate price upon request.
• Filed with the SEC on Oct 6, 2026; the filing date matches the usual Form 4 deadline for an Oct 2, 2026 transaction and is not shown as late.

Why it may matter

• The filing indicates a sell-to-cover tax-withholding sale tied to vesting of restricted stock units, not a discretionary market trade, option exercise, or gift.
• A filing does not show why the insider traded or why the company acted.